Bladder cancer relapse and quality of life study after TURBT
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tracks patients with early-stage bladder cancer after surgery (TURBT) to see how often the cancer returns and how it affects your daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have non-muscle invasive bladder cancer
- You need to have a surgery called TURBT to remove the cancer
- You can read and sign a consent form
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people feel and their health after having their bladder removed. It aims to understand quality of life after this surgery.
This trial studies a redesigned surgical instrument used during bladder tumor removal, to see if it can improve how the removed tissue samples are collected. It may help future patients by supporting better study of bladder tissue during cancer care.
This trial tests STM-416, given around the time you have surgery to remove recurring bladder tumors, to see if it can reduce the chance the cancer comes back. It is for people with high-risk early bladder cancer (non–muscle-invasive) who have already had standard treatment and now need another TURBT.
This trial studies a BCG-based bladder instillation in people with newly diagnosed, intermediate- or high-risk non-muscle invasive bladder cancer who have had their tumor fully removed. The goal is to see whether this treatment is safer and works better to lower the chance of the cancer coming back.
This trial tests a new blood test that looks for signs bladder cancer may be coming back in people with a recent history of bladder cancer. It may help by making surveillance easier, but you must still follow a scheduled bladder-check plan.
This clinical trial tests a new drug, BH011, for people with high-risk, non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. The goal is to see if the drug is safe and works well when given directly into the bladder, as an alternative to bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.